Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature

ABSTRACT

Gingivitis and periodontitis are common bacterial infections caused by a variety of microorganisms. Despite the microorganisms' roles as etiologic agents, inflammation-induced substances also have crucial parts in the loss of connective tissue and the supporting alveolar bone. Visfatin is a pleiotropic mediator, which acts as growth factor, cytokine, and pre-B-cell colony-enhancing factor. A positive correlation was detected between the serum/plasma levels of visfatin and inflammatory disorders such as diabetes mellitus and cardiovascular disease. In addition, the visfatin level was higher in saliva and the gingival crevicular fluid (GCF) of subjects with periodontal disease. This review defined current, predictable patterns of possible interaction of visfatin with periodontal infection and other systemic diseases, using PubMed and Medline databases searching for articles written in English. Peer-reviewed articles were targeted using the following keywords: “visfatin,” “periodontal disease,” “inflammatory mediator,” and “biomarker.” Available full-text articles were read, and related articles were also scrutinized, while a hand search was also performed. Search was confined to human studies, and articles written in English and published between 1985 and 2016 were selected. It was concluded that periodontal infection and other systemic diseases could be related to the levels of visfatin in GCF, saliva, and serum as a biomarker of these diseases.

 

MissingLinkText

Key words:

Biomarker - inflammatory mediator - periodontal disease - visfatin

INTRODUCTION

Periodontitis is a known oral infllammatory disease initiated through chronic bacterial infection. Based on the literature, Gram-negative anaerobic and aerophilic bacteria contained in the mouth’s biofiilm are responsible for disease initiation and progression.[1] In its acute form, chronic periodontitis destroys periodontal tissue fibers and the supporting bone which leads to apical migration of junctional epithelium and formation of deep periodontal pockets around the teeth. The untreated periodontal pockets host a variety of highly virulent microorganisms, and they lead to inflammatory-immune response and tissue destruction.[2] To decrease periodontal disease and its damage, there is a growing demand to locate the most specific and sensitive biomarker in saliva and gingival crevicular fluid (GCF). Biomarkers are defined as an indicator of normal biological or pathogenic processes, or as a pharmacologic response to a therapeutic intervention.[3]

In 2005, a new adipokine was identified and named visfatin (visceral fat adipokine).[4] It is identified as pre-B-cell colony-enhancing factor, which is involved in the early development of B- cell growth factor and cytokine-like effects, and it also has a role in energy metabolism. Visfatin is a 52-KDa protein, increasing pre-B-cell colony release from lymphocytes and improving maturation of B-lymphocytes.[5] Furthermore, production of interleukin-1 beta (IL-1 β), tumor necrosis factor alpha (TNF-α), and IL-6-induced by visfatin have also been reported during infection and inflammation.[6] Visfatin is also known as nicotinamide phosphoribosyltransferase, an enzyme inhibiting the biosynthesis of nicotinamide adenine dinucleotide.[7] Visfatin is secreted by visceral adipose tissue and macrophages. In addition, it is isolated from several tissues, such as white blood cells, lymphocytes, muscle, dendritic cells, and bone marrow.[8] Therefore, it is considered an inflammatory adipokine that is available in inflammatory cells and inflammatory conditions. For example, the expression of visfatin increases in acute and chronic inflammatory conditions.[9] This review defined current, predictable patterns of possible interaction of visfatin with periodontal infection and other systemic diseases, using PubMed and Medline databases searching for articles written in English. Peer-reviewed articles were targeted using the following keywords: “visfatin,” “periodontal disease,” “inflammatory mediator,” and “biomarker.” Available full-text articles were read, and related articles were also scrutinized, while a hand search was also performed. The articles written in English and published between 1985 and 2016 were selected.

 

MissingLinkText

DETECTION OF VISFATIN IN SALIVA AND GINGIVAL CREVICULAR FLUID

Saliva contains specific biomarkers, and specific changes in these markers might help the diagnosis of periodontitis. Salivary levels of visfatin are an acceptable alternative in the evaluation of inflammatory conditions.[10] [11] It was reported that the levels of salivary resistin, visfatin, and adiponectin was correlated with serum hormonal levels.[12] For example, GCF is in close contact with periodontal tissues; therefore, GCF levels reflect the status of this tissue. In fact, the vast levels of cytokines present in GCF are potentially useful for diagnosis of periodontal disease.[13] Visfatin exists in both saliva and GCF, and its levels alter depending on physiologic and pathophysiologic conditions. In addition, visfatin levels was determined in the GCF of healthy individuals and patients with periodontitis, and the study investigated the possible relationship between this adipokine and the presence and levels of Porphyromonas gingivalis, Prevotella intermedia, Prevotella nigrescense, and the Epstein-Barr virus (EBV).[14] It was concluded that the presence of EBV in oral plaque may be another factor that causes an increase in visfatin levels.

 

MissingLinkText

VISFATIN AND PERIODONTAL DISEASE

Despite reports on the role of visfatin as a marker in periodontal diseases,[15] only a few studies have been conducted in this area. One study[16] found a correlation between visfatin and the progress of periodontal disease. In this study, the relationship between the serum and GCF concentrations of visfatin and periodontal diseases was evaluated and it was eventually concluded that concentrations of visfatin in the serum and GCF progressively increased among patients suffering a range of gum diseases from gingivitis to periodontitis. In addition, the concentration of visfatin was higher in patients with periodontal disease and type 2 diabetes mellitus (T2DM) compared to individuals with the periodontal disease but without T2DM. Tabari et al.[17] reported a relationship existed between salivary visfatin and chronic periodontitis in which salivary visfatin concentrations elevated during periodontal infection. Another study[18] stated that salivary visfatin levels were significantly higher in the gingivitis and periodontitis subjects when compared to those in the healthy subjects.

In addition, Özcan et al.[19] investigated the expression of visfatin, NF-κB (NF-κB1 and NF-κB2), PI3k, TNF-α, and IL-1 β in the tissues of healthy individuals and patients with periodontitis. They revealed increased visfatin levels were associated with the expression of NF-κB and PI3k, which may play a role in the pathogenesis of periodontitis. We suggest that increased visfatin may contribute to the inhibition of neutrophil apoptosis through the NF-κB and PI3k signaling pathways.

 

MissingLinkText

ALTERATION IN VISFATIN LEVELS AND PERIODONTAL THERAPY

It was reported that both serum and GCF concentrations of visfatin decreased after periodontal treatment.[20]

Decreased levels of this cytokine after periodontal therapy may lessen the risks associated with the condition, and visfatin is targeted for its therapeutic potential in the treatment of periodontal diseases. In comparison, Abolfazli et al.[21] evaluated the effect of nonsurgical periodontal treatment on serum and salivary levels of visfatin. They found decreased clinical parameters of P laque index, gingival index, probing pocket depth, clinical attachment levels following nonsurgical periodontal treatment.

In the latest study[22] that compared changes in the levels of visfatin, decreased amount of GCF was found in healthy subjects as well as in subjects with periodontitis, with or without controlled T2DM, after administration of nonsurgical periodontal therapy. It was concluded that visfatin levels are highest in individuals with both periodontal disease and diabetes, even after periodontal therapy. Individuals with T2DM may be at higher risk of developing periodontal disease.

 

MissingLinkText

THE LINK BETWEEN VISFATIN AND TYPE 2 DIABETES MELLITUS

Furthermore, one of the main risk factors for insulin resistance and T2DM is excess adiposity. Adipose tissue produces numerous adipocytokines include leptin, adiponectin, resistin, visfatin, TNF, and IL-6. In addition, it is able to modulate insulin sensitivity in diabetes, dyslipidemia, inflammation, and atherosclerosis. However, the mechanisms of adipocytokines in the pathogenesis of T2DM were not fully elicited.[23]

The dual effects of visfatin as an adipocytokine, specifically as a global insulin-imitator and local adipogenic, have created a therapeutic challenge for visfatin in the treatment of T2DM.[24] However, mechanisms have been introduced that explain how visfatin acts on a cellular level. In brief, visfatin binds to insulin receptors and stimulates glucose uptake in adipocytes and muscle cells while suppressing glucose release from the hepatocytes.[25] For example, Haider et al.[26] found plasma visfatin levels increased with elevated blood glucose. The expression of visfatin up-regulated in a glucose-dependent manner in cultured adipocytes.[27] In healthy volunteers taking a glucose tolerance test, visfatin increased with deteriorated insulin secretion reactions to glucose.[28] These results displayed the relationship between serum visfatin and the inflammatory state in T2DM.

 

MissingLinkText

VISFATIN AND OBESITY

It is reported that plasma visfatin is high in overweight or obese patients. The abundance of adipose tissue in these patients is responsible for elevated levels of visfatin.[29]-[31] Choi et al.[32] reported the level of visfatin was higher in Korean obese women participants when compared to nonobese participants. They also detected a correlation with plasma visfatin and body weight reduction using an exercise program.

 

MissingLinkText

VISFATIN AND POLYCYSTIC OVARY SYNDROME

Polycystic ovarian syndrome (PCOS) is a multifaceted metabolic disease associated with insulin resistance and obesity. Women exhibiting PCOS have higher plasma levels of visfatin. In addition, the visfatin level in the subcutaneous and visceral adipose tissues was higher among women with PCOS.[33]

 

MissingLinkText

VISFATIN AND CARDIOVASCULAR DISEASE

One study[34] revealed that visfatin levels increased in patients with cardiovascular disease. Visfatin plays a key role in the pathogenesis of macrovascular diseases. Moreover, visfatin levels are high in the atherogenic plaque of patients with acute myocardial infarction. Matrix metalloproteinase two and nine expressions were activated by visfatin in human endothelial cells. Therefore, there was a correlation between visfatin and atherogenic plaque instability,[35] implying an interaction between visfatin and inflammatory atherosclerotic diseases. Visfatin was high, significantly expressed in symptomatic atherosclerotic carotid plaques, and it was localized to areas with lipid-loaded macrophages.[36]

 

MissingLinkText

CONCLUSION

Visfatin in GCF, saliva, and serum can be considered an inflammatory biomarker in periodontal disease. Periodontal disease progression has been identified as a predictor of high-risk diseases such as diabetes and cardiovascular diseases. Periodontal infection influences the systemic inflammatory reaction by upregulating pro-inflammatory agents such as visfatin. Further research can be conducted to determine visfatin effects on human periodontal conditions. According to the findings of this review, it is tempting to hypothesize that visfatin levels can be considered a possible link between periodontal infection and other systemic diseases.

Financial support and sponsorship

Nil.

 

MissingLinkText

 

MissingLinkText

 

MissingLinkText

Conflicts of interest

There are no conflicts of interest.

• REFERENCES

• 1 Armitage GC. Periodontal diagnoses and classification of periodontal diseases. Periodontol 2000 2004; 34: 9-21
• 2 Hanes PJ, Krishna R. Characteristics of inflammation common to both diabetes and periodontitis: Are predictive diagnosis and targeted preventive measures possible?. EPMA J 2010; 1: 101-16
• 3 Taba Jr. M, Kinney J, Kim AS, Giannobile WV. Diagnostic biomarkers for oral and periodontal diseases. Dent Clin North Am 2005; 49: 551-71, vi
• 4 Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K. et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-30
• 5 Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-7
• 6 Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H. et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-58
• 7 Garten A, Petzold S, Barnikol-Oettler A, Körner A, Thasler WE, Kratzsch J. et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 2010; 391: 376-81
• 8 Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R. et al. Macrophages in human visceral adipose tissue: Increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-7
• 9 Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56: 565-70
• 10 Ozmeric N. Advances in periodontal disease markers. Clin Chim Acta 2004; 343: 1-16
• 11 Kaufman E, Lamster IB. Analysis of saliva for periodontal diagnosis – A review. J Clin Periodontol 2000; 27: 453-65
• 12 Mamali I, Roupas ND, Armeni AK, Theodoropoulou A, Markou KB, Georgopoulos NA. Measurement of salivary resistin, visfatin and adiponectin levels. Peptides 2012; 33: 120-4
• 13 Todorovic T, Dozic I, Vicente-Barrero M, Ljuskovic B, Pejovic J, Marjanovic M. et al. Salivary enzymes and periodontal disease. Med Oral Patol Oral Cir Bucal 2006; 11: E115-9
• 14 Özcan E, Saygun NI, Serdar MA, Kubar A, Bengi VU. Porphyromonas gingivalis and Epstein-barr virus are associated with increased levels of visfatin in gingival crevicular fluid. J Periodontol 2016; 87: 443-51
• 15 Pradeep AR, Raghavendra NM, Sharma A, Patel SP, Raju A, Kathariya R. et al. Association of serum and crevicular visfatin levels in periodontal health and disease with type 2 diabetes mellitus. J Periodontol 2012; 83: 629-34
• 16 Pradeep AR, Raghavendra NM, Prasad MV, Kathariya R, Patel SP, Sharma A. Gingival crevicular fluid and serum visfatin concentration: Their relationship in periodontal health and disease. J Periodontol 2011; 82: 1314-9
• 17 Tabari ZA, Azadmehr A, Nohekhan A, Naddafpour N, Ghaedi FB. Salivary visfatin concentrations in patients with chronic periodontitis. J Periodontol 2014; 85: 1081-5
• 18 Özcan E, Saygun NI, Serdar MA, Kurt N. Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation. Clin Oral Investig 2015; 19: 921-8
• 19 Özcan E, Saygun NI, Ilikçi R, Karslioglu Y, Musabak U, Yesillik S. Increased visfatin expression is associated with nuclear factor-kappa B and phosphatidylinositol 3-kinase in periodontal inflammation. Clin Oral Investig 2017; 21: 1113-21
• 20 Raghavendra NM, Pradeep AR, Kathariya R, Sharma A, Rao NS, Naik SB. Effect of non surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease. Dis Markers 2012; 32: 383-8
• 21 Abolfazli N, Jabali S, Saleh Saber F, Babaloo Z, Shirmohammadi A. Effect of non-surgical periodontal therapy on serum and salivary concentrations of visfatin in patients with chronic periodontitis. J Dent Res Dent Clin Dent Prospects 2015; 9: 11-7
• 22 Mishra V, Shettar L, Bajaj M, Math AS, Thakur SL. Interlinking periodontitis and type 2 diabetes mellitus by assessment of crevicular visfatin levels in health and in disease before and after initial periodontal therapy. J Clin Diagn Res 2016; 10: ZC67-71
• 23 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 01) S62-9
• 24 Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-9
• 25 Hug C, Lodish HF. Medicine. Visfatin: A new adipokine. Science 2005; 307: 366-7
• 26 Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-81
• 27 Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-14
• 28 López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, Casamitjana R. et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-5
• 29 Iacobellis G, Iorio M, Napoli N, Cotesta D, Zinnamosca L, Marinelli C. et al. Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest 2011; 34: 12-5
• 30 Schutte AE, Huisman HW, Schutte R, van Rooyen JM, Malan L, Fourie CM. et al. Adipokines and cardiometabolic function: How are they interlinked?. Regul Pept 2010; 164: 133-8
• 31 Unlütürk U, Harmanci A, Yildiz BO, Bayraktar M. Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol (Oxf) 2010; 72: 469-74
• 32 Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol 2007; 157: 437-42
• 33 Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome. Diabetologia 2006; 49: 2723-8
• 34 Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515-27
• 35 Adya R, Tan BK, Chen J, Randeva HS. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: Its role in MMP-2/9 production and activation. Diabetes Care 2008; 31: 758-60
• 36 Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A. et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-80